Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Predictive Values of EGFR expression for the Fluoropyrimidine Metronomic Maintenance Therapy in Patients with Stage III Colorectal Cancer after Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy

Version 1 : Received: 18 December 2019 / Approved: 19 December 2019 / Online: 19 December 2019 (07:04:39 CET)

How to cite: Huang, C.; Ma, C.; Chen, Y.; Tsai, H.; Yeh, Y.; Su, W.; Chang, T.; Hsu, W.; Yu, F.; Wang, J. Predictive Values of EGFR expression for the Fluoropyrimidine Metronomic Maintenance Therapy in Patients with Stage III Colorectal Cancer after Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy. Preprints 2019, 2019120246 (doi: 10.20944/preprints201912.0246.v1). Huang, C.; Ma, C.; Chen, Y.; Tsai, H.; Yeh, Y.; Su, W.; Chang, T.; Hsu, W.; Yu, F.; Wang, J. Predictive Values of EGFR expression for the Fluoropyrimidine Metronomic Maintenance Therapy in Patients with Stage III Colorectal Cancer after Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy. Preprints 2019, 2019120246 (doi: 10.20944/preprints201912.0246.v1).

Abstract

Background: This retrospective study evaluates the survival effects of metronomic maintenance therapy with fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. Methods: We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study and in vivo study through knockdout of EGFR gene, we analyzed the capacities of cell proliferation and migration. Results: Postoperative relapse and mortality were significantly more common in the FOLFOX group. Metronomic maintenance therapy was a significantly independent predictive factor of postoperative relapse and mortality, as well as a prognostic factor of disease-free survival and overall survival. The significant differences of survival between the two groups were only observed in patients with positive EGFR expression. Conclusions: The present study suggested EGFR expression as the prognostic factor in patients with stage III CRC receiving metronomic maintenance therapy. By analyzing EGFR expression, we can identify the potential candidates with optimal survival benefit from metronomic maintenance therapy in patients with stage III CRC.

Subject Areas

fluoropyrimidine; metronomic maintenance therapy; oxaliplatin-based regimen; stage III colorectal cancer; epidermal growth factor receptor

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.